Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesAccesswire • 05/24/23
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsAccesswire • 05/11/23
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting PackageAccesswire • 04/20/23
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial ResultsAccesswire • 02/21/23
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe RosaceaAccesswire • 12/05/22
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsAccesswire • 11/10/22
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAccesswire • 09/06/22
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsAccesswire • 08/15/22
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe RosaceaAccesswire • 06/13/22
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsAccesswire • 05/16/22
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesAccesswire • 04/25/22
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesAccesswire • 04/21/22
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial ResultsAccesswire • 03/28/22